for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Zafgen Inc

ZFGN.OQ

Latest Trade

0.78USD

Change

0.01(+1.20%)

Volume

110,519

Today's Range

0.75

 - 

0.78

52 Week Range

0.64

 - 

12.36

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.77
Open
0.76
Volume
110,519
3M AVG Volume
10.92
Today's High
0.78
Today's Low
0.75
52 Week High
12.36
52 Week Low
0.64
Shares Out (MIL)
37.37
Market Cap (MIL)
27.67
Forward P/E
-0.60
Dividend (Yield %)
--

Latest Developments

More

Zafgen Says Compensation Committee Commenced A Reduction In Force And Retention Plan

Zafgen Q2 Loss Per Share $0.32

Zafgen Announces Agreement With U.S. Food And Drug Administration On New Nonclinical Study Design For Zgn-1061

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Zafgen Inc

Zafgen, Inc., is a clinical-stage biopharmaceutical company. The Company uses its proprietary methionine aminopeptidase 2 (MetAP2) biology platform to develop novel therapies for patients affected by complex metabolic diseases. Its product candidate is ZGN-1061 which is a novel fumagillin-class MetAP2 inhibitor that is used to treat type 2 diabetes and other related metabolic disorders. Type 2 diabetes is a prevalent, chronic, progressive and multifactorial disorder that leads to increased microvascular and macrovascular disease and as such increases risk of death from cardiovascular disease, stroke, and kidney failure. Its MetAP2 development candidate ZGN-1258 is administered by subcutaneous injection. ZGN-1258 is used for the treatment of Prader-Willi syndrome (PWS). PWS is a rare and complex genetic disorder characterized by physiologic, cognitive and behavioral symptoms including hyperphagia, uncontrollable hunger and its related behaviors, and obesity.

Industry

Biotechnology & Drugs

Contact Info

3 Center Plz Ste 610

+1.617.6224003

http://www.zafgen.com/

Executive Leadership

Peter Barrett

Independent Chairman of the Board

Jeffrey S. Hatfield

Chief Executive Officer, Director

Patricia L. Allen

Chief Financial Officer

Brian P. McVeigh

Chief Business Officer

Priya Singhal

Head of Research and Development

Key Stats

3.00 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-2.120

2017

-1.900

2018

-1.900

2019(E)

-1.228
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
0.38
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
26.51
LT Debt To Equity (MRQ)
16.43
Return on Investment (TTM)
-68.19
Return on Equity (TTM)
-59.75

Latest News

FDA puts Zafgen's diabetes trial on hold

Zafgen Inc said on Monday the U.S. Food and Drug Administration had placed a clinical hold on U.S. trials of its experimental diabetes drug, citing possible heart safety risks.

U.S. FDA puts Zafgen's diabetes trial on hold

Zafgen Inc said on Monday the U.S. Food and Drug Administration (FDA) had placed a clinical hold on the investigational new drug application for a trial of its experimental diabetes drug.

BRIEF-Zafgen Reports Q1 Loss Per Share $0.58

* ZAFGEN REPORTS FIRST QUARTER 2018 OPERATING AND FINANCIAL RESULTS

BRIEF-Zafgen Reports Q4 Loss Per Share $0.48

* ZAFGEN REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS; ANNOUNCES POSITIVE INTERIM DATA FROM ONGOING ZGN-1061 PHASE 2 PROOF-OF-CONCEPT TRIAL IN PATIENTS WITH TYPE 2 DIABETES

BRIEF-Zafgen Says Co Entered Into Loan And Security Agreement Providing For Term Loan With Principal Amount​ Of $20 Mln

* ZAFGEN SAYS ON DEC 29, CO ENTERED INTO LOAN AND SECURITY AGREEMENT PROVIDING FOR TERM LOAN WITH PRINCIPAL AMOUNT OF $20 MILLION - SEC FILING Source text: [http://bit.ly/2Earwn6] Further company coverage:

BRIEF-Zafgen Reports Strong Clinical Progress And Updates Outlook For 2018

* ZAFGEN REPORTS STRONG CLINICAL PROGRESS AND UPDATES OUTLOOK FOR 2018

BRIEF-Zafgen reports Q3 loss per share $0.46

* Q3 earnings per share view $-0.58 -- Thomson Reuters I/B/E/S

BRIEF-Zafgen appoints Jeffrey Hatfield as CEO

* Zafgen appoints Jeffrey Hatfield as Chief Executive Officer; Thomas Hughes, Ph.D. to continue as president, appointed chief scientific officer

BRIEF-Zafgen initiates Phase 2 clinical trial for ZGN-1061

* Zafgen initiates Phase 2 clinical trial for ZGN-1061 in patients with Type 2 diabetes Source text for Eikon: Further company coverage:

BRIEF-Zafgen Inc files for a potential mixed shelf offering of up to $150 mln

* Zafgen Inc files for a potential mixed shelf offering of up to $150 million - SEC filing Source text: (http://bit.ly/2vkwJqL) Further company coverage:

BRIEF-Zafgen Q2 loss per share $0.49

* Q2 earnings per share view $-0.52 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-Zafgen preclinical abstract will present results for zgn-1061 on glycemic control, weight loss and safety profile

* Zafgen to present two late-breaking abstracts for zgn-1061 at the american diabetes association 77th scientific sessions

BRIEF-Zafgen announces positive topline phase 1 data for ZGN-1061

* Zafgen announces positive topline phase 1 data for ZGN-1061, a second generation METAP2 inhibitor

BRIEF-Zafgen reports Q3 loss per share $0.54

* Q3 earnings per share view $-0.61 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-Zafgen initiates multiple ascending dose cohorts in early stage clinical trial of ZGN-1061

* Zafgen initiates multiple ascending dose cohorts in phase 1 clinical trial of ZGN-1061

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up